Rituximab. Chronic lymphoid leukaemia: no decisive advantage.

  • Published 2010 in Prescrire international

Abstract

When treatment is needed for patients with symptomatic chronic lymphoid leukaemia, the standard first-line treatment is oral chlorambucil. Fludarabine has been used more as a second-line option. Rituximab has been authorised for use in both first-line and second-line therapy. We found no randomised trials comparing rituximab versus either chlorambucil or… (More)

Topics

  • Presentations referencing similar topics